IDEAYA Biosciences (IDYA) Reports Q4 Loss of $0.18/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IDYA Hot Sheet
Join SI Premium – FREE
IDEAYA Biosciences (NASDAQ: IDYA) reported Q4 EPS of ($0.18), versus ($0.53) reported last year. Revenue for the quarter came in at $10.57 million, versus $0 reported last year.
For earnings history and earnings-related data on IDEAYA Biosciences (IDYA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- Revolution Medicines, Inc. (RVMD) Tops Q3 EPS by 45c ; Provides Outlook
- Amcor plc (AMCR) Misses Q1 EPS by 9c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
